Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Schistosoma mansoni | Thioredoxin glutathione reductase | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | integrin beta 2 | 0.0261 | 0.6944 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0116 | 0.2091 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0135 | 0.2728 | 0.2728 |
Schistosoma mansoni | integrin alpha | 0.0172 | 0.3965 | 0.728 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0116 | 0.2091 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0095 | 0.1384 | 0.1384 |
Echinococcus multilocularis | integrin alpha 3 | 0.0132 | 0.2621 | 0.2977 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0116 | 0.2091 | 1 |
Echinococcus granulosus | integrin alpha 3 | 0.0132 | 0.2621 | 0.2977 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0116 | 0.2091 | 1 |
Schistosoma mansoni | integrin beta subunit | 0.0207 | 0.5152 | 1 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.0265 | 0.7083 | 0.7083 |
Loa Loa (eye worm) | hypothetical protein | 0.013 | 0.2563 | 0.2563 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0172 | 0.3965 | 0.3965 |
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.013 | 0.2563 | 0.2563 |
Loa Loa (eye worm) | integrin beta-2 | 0.0352 | 1 | 1 |
Echinococcus multilocularis | integrin beta 2 | 0.0261 | 0.6944 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 4.4668 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia. (Class of assay: confirmatory) [Related pubchem assays: 2472, 2464 ] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 75.193 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.